Grifols signs an agreement with ImmunoTek to open 21 plasma centers and further advances on its expansion plan
- Grifols reaffirms its commitment to expanding its plasma supply to meet the growing demand for plasma therapies
- Grifols will develop 21 additional plasma collection centers through a collaboration with ImmunoTek
- Once all centers become operative and ramped-up, collectively they will supply an additional plasma capacity of 1 million liters annually
- 5 centers are currently in operation. It is foreseen that all the 21 centers will be established and operating by October 2022
- Grifols has committed to fund these operations
Barcelona, July 30, 2021.- Grifols (MCE: GRF, MCE: GRF.P y NASDAQ: GRFS), a global leader in the production of plasma-derived medicines with more than 100 years of history dedicated to enhancing people’s health and well-being, closed a collaboration agreement with the U.S. firm ImmunoTek Bio Centers LLC, specialized in the opening and construction of plasma centers via strategic accords and contracts with healthcare companies. Through this accord, Grifols will accelerate the execution of its expansion plan and bolster its integrated network of plasma centers.
Grifols and ImmunoTek will combine their expertise for the development, construction and operation of 21 plasma collection centers with a capacity of 1 million liters of plasma per year.
Out of the total 21 centers in the agreement, 5 are already operating and are currently in the ramp-up phase. All 21 plasma collection centers will be established and functioning by October 2022. Grifols will have access to the plasma from the 5 centers in operation.
For Eduardo Herrero, President of Grifols Bioscience Industrial Group, “Plasma is one of the central pillars of Grifols’ long-term, sustainable growth strategy. This agreement allows us to free up internal operating resources and focus on promoting, optimizing and expanding the capacity of our current plasma-center network, while working to open new centers with an exceptional partner like ImmunoTek.”
ImmunoTek CEO Jerome Parnell III said, “This patnership continues ImmunoTek’s aggressive expansion, and we are very pleased to have a leader like Grifols as a close partner.”
Grifols remains committed to further expanding its plasma availability to meet anticipated robust demand and guarantee the supply of essential plasma therapies for patients who need them.
About the agreement with ImmunoTek
Under the agreement, ImmunoTek will manage the centers in accordance with a business plan previously arranged with Grifols. All centers are expected to be licensed by the U.S. Food and Drug Administration (FDA) and European health authorities.
The centers will exclusively serve Grifols manufacturing needs.
Grifols has committed to fund the opening and development of the centers.
Grifols retained the legal services of Osborne Clarke S.L.P. and Proskauer Rose L.L.P. for this transaction.
Acquisition of 32 plasma centers in the United States in 1H 2021 provides access to 1.4 million additional liters of plasma per year
Prior to this agreement, Grifols closed the acquisition of 32 plasma centers in the United States in the first semester of 2021, another step forward toward consolidating the leadership of its global network. Specifically, Grifols acquired 25 centers from BPL Plasma Inc. in March 2021 and seven plasma centers from Kedrion in April 2021.
These centers will provide an additional capacity of roughly 1.4 million liters of plasma per year, which the company can immediately access.
Additionally Grifols also plans on opening 15 to 20 new plasma centers in the second half of 2021.